Trials / Recruiting
RecruitingNCT06794541
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Intravenous Eravacycline in Pediatric Patients From 8 Years to Less Than 18 Years of Age With Complicated Intra-abdominal Infections (cIAI)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Tetraphase Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 8 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eravacycline 2mg/kg | intravenous (IV) infusion |
| DRUG | Eravacycline 1.5mg/kg | intravenous (IV) infusion |
Timeline
- Start date
- 2025-05-22
- Primary completion
- 2029-02-17
- Completion
- 2029-03-19
- First posted
- 2025-01-27
- Last updated
- 2025-10-29
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06794541. Inclusion in this directory is not an endorsement.